EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis

Yanquan Zhang, Ka-Wing Fong, Fengyi Mao, Ruixin Wang, Derek B Allison, Dana Napier, Daheng He, Jinpeng Liu, Yeqing Zhang, Jing Chen, Yifan Kong, Chaohao Li und 6 weitere

Cell Reports · 2024

DOI: 10.1016/j.celrep.2024.114431 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Yanquan Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexingto…. Hauptthemen laut MEDLINE: Polo-Like Kinase 1, Cell Cycle Proteins, Prostatic Neoplasms, Proto-Oncogene Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polo-Like Kinase 1Cell Cycle ProteinsProstatic NeoplasmsProto-Oncogene ProteinsMitosisProtein Serine-Threonine KinasesTranscription FactorsDrug Resistance, NeoplasmAzepinesTriazolesDocetaxelHumansMalePhosphorylationCell Line, TumorProteolysisNuclear ProteinsAnimalsCDC2 Protein KinaseMice, NudeMiceProteasome Endopeptidase ComplexBromodomain Containing ProteinsRepressor Proteins

Stichwörter der Autor:innen

APC/C(Cdh1)BET inhibitor resistanceBRD4CP: CancerCP: Molecular biologyPLK1phosphorylationprostate cancer

Substanzen

Polo-Like Kinase 1Cell Cycle ProteinsProto-Oncogene ProteinsBRD4 protein, humanProtein Serine-Threonine KinasesTranscription FactorsAzepinesTriazolesDocetaxelNuclear Proteins

Autor:innen und Institutionen

  • Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA. Electronic address: yanquan.zhang@uky.edu.
  • Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
  • Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, KY 40536, USA.
  • Pathology & Laboratory Medicine, University of Kentucky, Lexington, KY 40508, USA.
  • Biospecimen Procurement & Translational Pathology Shared Resource Facility, University of Kentucky, Lexington, KY 40536, USA.
  • Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY 40536, USA; Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NCATS NIH HHS
  • American Cancer Society
  • National Institute of General Medical Sciences
  • NIH
  • Eastern Kentucky University
  • Markey Cancer Center, University of Kentucky

Zitieren

APA

Zhang, Y., Fong, K. W., Mao, F., Wang, R., Allison, D. B., Napier, D., He, D., Liu, J., Zhang, Y., Chen, J., Kong, Y., Li, C., Li, G., Liu, J., Li, Z., Zhu, H., Wang, C., & Liu, X. (2024). Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114431

Vancouver

Zhang Y, Fong KW, Mao F, Wang R, Allison DB, Napier D, et al. Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114431

BibTeX
@article{Zhang2024,
  author = {Zhang, Yanquan and Fong, Ka-Wing and Mao, Fengyi and Wang, Ruixin and Allison, Derek B and Napier, Dana and He, Daheng and Liu, Jinpeng and Zhang, Yeqing and Chen, Jing and Kong, Yifan and Li, Chaohao and Li, Guangbing and Liu, Jinghui and Li, Zhiguo and Zhu, Haining and Wang, Chi and Liu, Xiaoqi},
  title = {Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis},
  journal = {Cell Reports},
  year = {2024},
  doi = {10.1016/j.celrep.2024.114431}
}
Kostenlos starten →